PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY - AN UPDATED ANALYSIS
May 1, 2010, 00:00
10.1016/S1098-3015(10)72171-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)72171-9/fulltext
Title :
PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY - AN UPDATED ANALYSIS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72171-9&doi=10.1016/S1098-3015(10)72171-9
First page :
Section Title :
Open access? :
No
Section Order :
753